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Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) and bronchiectasis, chronic inflammation disorders of the bron-
chial tree through the mechanism of ‘spill-over’ of inflammatory mediators, may lead to systemic manifestations of illness of the 
respiratory system and comorbidities.
The aim of the study was to evaluate the frequency of coexisting COPD and bronchiectasis and influence of bronchiectasis on 
COPD comorbid diseases.
Material and methods: A post-hoc cross-sectional analysis of cohort study of 288 consecutive patients hospitalized due to acute 
exacerbation of COPD was performed. 
Results: 177 males (61.5%) and 111 females (38.5%) with mean age = 71.0 8 ± 8.9 years, FEV1% pred. = 34.6 ± 16.8 with 
COPD diagnosis were studied. In this group, 29 (10.1%) patients presented with bronchiectasis confirmed by HRCT scan. COPD 
patients with and without bronchiectasis had similar Charlson index results (2.5 vs 2.1, p = 0.05). COPD patients with bronchiec-
tasis required longer hospitalization during exacerbation. COPD patients with bronchiectasis significantly more often than patients 
without this comorbidity revealed the features of colonization with P. aeruginosa (OR = 4.17, p = 0.02). 
Conclusions: Bronchiectasis is a relatively common comorbidity in COPD patients. COPD patients with bronchiectasis are more 
frequently colonized with P. aruginosa comparing to non-bronchiectasis COPD patients. We did not confirm the influence of bron-
chiectasis on COPD comorbidities. 
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Introduction
Bronchiectasis is a relatively uncommon 
disease, characterized by airway dilatation and 
airway wall thickening associated with symptoms 
of persistent or recurrent bronchial infection, 
often secondary to various disorders causing chro-
nic airway inflammation [1]. COPD is diagnosed 
based on poorly reversible airflow obstruction 
with an abnormal inflammatory response of the 
lung to cigarette smoke and other stimuli [2]. An 
increasing number of patients with COPD have a 
CT scan as part of their diagnosis and follow-up 
care, with a consequent impact on the detection 
of bronchiectasis [3]. COPD is a systemic disease 
with well-defined comorbidities. Diagnosis of 
diseases concomitant with COPD is of clinical 
importance as recognition of comorbidity is 
a significant predictive factor [4, 5]. Generally, di-
seases concomitant with COPD should be treated 
in accordance with current detailed guidelines on 
particular comorbidities, and diagnosis of COPD 
should not result in decreased intensity of therapy 
[2]. However, there are clinical scenarios when 
the recognition of specific comorbid disease has 
not only prognostic value but also leads to treat-
ment modification or a change in another medical 
procedure. Diagnosis of COPD in the patient with 
heart failure encourages doctors to order more 
selective beta blockers, whereas the diagnosis of 
concomitant osteoporosis induces them to use 
cautiously systemic steroids [6, 7]. 
It seems that recognition of comorbid bron-
chiectasis in COPD patients is the occasion when 
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standard treatment of COPD patients’ needs to be 
modified. When bronchiectasis is diagnosed in 
COPD patients, exacerbations may need longer 
treatment [9]. Moreover, in this group of subjects, 
recognition of bronchiectasis is also an adverse 
prognostic factor [10]. In the case of both con-
ditions, i.e. COPD and bronchiectasis, chronic 
inflammation of the bronchial tree occurs, which, 
through the mechanism of ‘spill-over’ of inflam-
matory mediators [11], may lead to systemic ma-
nifestations of illness of the respiratory system. 
Anti-inflammatory treatment in COPD patients 
acts in many directions, one of them is the chronic 
use of inhaled steroids. According to the GOLD 
guidelines, the use of inhaled steroids should be 
considered in patients with a severe form of the 
disease and frequent exacerbations [12, 13]. In 
bronchiectasis, treatment with inhaled steroids is 
not recommended [1]. In order to reduce inflamma-
tory status in the case of bronchiectasis in patients 
with frequent exacerbations, long-lasting oral [14] 
or inhaled [15] antibiotic therapy may be given. 
In many cases it is difficult to adopt an ap-
propriate treatment in the event of coexistence 
of COPD and bronchiectasis, particularly when 
there is a possibility of complications such as 
pneumonia after treatment with steroids or bac-
terial dysbiosis after therapy with inhaled anti-
biotics. It may be speculated that a pneumonia 
after treatment with inhaled steroids, which 
were observed in large post-marketing cohort 
studies in patients with diagnosed COPD, may 
be the result of the underdiagnosis of comorbid 
bronchiectasis [16].
There are studies on the impact of anti-in-
flammatory treatment on the frequency and 
course of concomitant diseases in COPD. There 
are no such studies concerning bronchiectasis. 
Aim: The aim of the study was to evaluate the 
frequency of coexisting chronic obstructive pul-
monary disease and bronchiectasis and influence 
of bronchiectasis on COPD comorbid diseases.
Study design: Cross-sectional, post-hoc 
analysis of prospective cohort study.
Setting: A single respiratory medicine depart-
ment in the tertiary teaching hospital.
Materials and methods
The study was based on a post-hoc analysis of 
data collected on a prospective basis in a single cen-
tre study, focusing on predictive factors in COPD. 
The cross-sectional analysis of the group of 
288 consecutive patients hospitalized due to acute 
exacerbation of COPD in the Second Department of 
Respiratory Medicine, National Research Institute 
of Tuberculosis and Lung Disease was performed. 
The subjects were referred to the department from 
the Hospital Emergency Department as urgent 
admissions, from specialist outpatient clinics 
(including outpatient clinic for patients with chro-
nic respiratory failure) or transferred from other 
hospitals due to difficulties in treatment.
In a hospital, all patients were assessed accor-
ding to the current guidelines, COPD diagnoses 
were confirmed following global and local guide-
lines [2, 17], diagnoses of bronchiectasis ware ba-
sed on the high-resolution computed tomography 
(HRCT) scanning in line with the BTS guidelines 
[1]. According to the standard procedure of the 
original study, all patients were carefully exami-
ned for comorbidities. The diagnoses were made 
by a group of respiratory and internal medicine 
specialists and were established in compliance 
with current international guidelines. Comor-
bidity has been defined as a disease coexisting 
with the primary disease of interest as suggested 
by Sin et al. [18]. The list of diagnoses of each 
patient including comorbidities was recorded in 
an electronic database. After the initial treatment 
of acute exacerbation of COPD, all patients were 
offered short time hospital-based pulmonary 
rehabilitation. During the rehabilitation, usually 
about a week after hospital admission, the six-mi-
nute walk test was performed [19]. 
The diseases were counted and grouped 
into typical comorbidity groups as proposed by 
Charlson [20] and other authors investigating 
comorbidities in respiratory medicine [11, 21, 22].
Microbiological sputum cultures were or-
dered in all patients, according to local hospital 
guidelines. No procedure of induced sputum 
was used. As spirometry was performed during 
the resolution of disease exacerbation, usually 
a couple of days after admission to the hospital. 
Patients stratification according to the disease 
severity were performed based on the obtained 
results of forced expiratory volume in one second 
(FEV1), measured after inhalation of a 400 µg of 
salbutamol. The analyzed laboratory parameters 
included haemoglobin concentration in periphe-
ral blood, biochemistry in serum, as well as blood 
gas analysis performed in arterialized venous 
blood, sampled directly on admission. Basing 
on the results of haemoglobin concentration, 
analysis of peripheral blood was performed and 
anaemia was diagnosed according to the respec-
tive World Health Organization (WHO) criteria. 
All physicians were free to order any additional 
tests and radiological assessments. 
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The study was approved by the local Ethics 
Committee of National Research Institute of Tu-
berculosis and Lung Disease (No KB-57). Post-hoc 
analysis of the study was performed in 2016, 
using the original study database and the hospital 
electronic database.
Statistical analysis
Variables are expressed as means and stan-
dard deviation in the case of quantitative variab-
les and as percentages and absolute numbers in 
the case of qualitative variables. A comparison 
of dichotomous variables was made using the x2 
test. The Kolmogorov-Smirnov test was used to 
check the normality of variables distribution. The 
Student t test was used to examine the differen-
ce between the means with normal distribution 
variables or the Mann-Whitney U test when the 
test of normality failed. 
Odds ratio calculation was used to compute 
the ratio of the odds of the outcomes in both 
studied groups. 
All results were considered to be statistically 
significant at p < 0.05.
Statistics analyses were performed using 
MedCalc software 16.2.1 (MedCalc Software, 
Acacialaan 22, B-8400 Ostend, Belgium).
Results
288 patients with the diagnosis of COPD 
were identified. 177 males (61.5%) and 111 
females (38.5%) with mean age = 71.0 8 ± 8.9 
years, FEV1% pred. = 34.6 ± 16.8 with COPD 
diagnosis were studied. In this group, 29 (10.1%) 
patients presented with bronchiectasis, all con-
firmed by HRCT scan performed before or during 
actual hospitalization (Table 1). No statistically 
significant differences regarding age or sex were 
found between the studied groups. Similarly, no 
differences relating to obstruction severity in 
COPD patients with and without bronchiectasis 
were discovered. Patients with COPD and bron-
chiectasis showed significantly lowered oxygen 
partial pressure, compared to the group of COPD 
patients without bronchiectasis (57.6 ± 12.2 
mm Hg vs 61.11 ± 1.5, p = 0.029). Similarly, pa-
tients with COPD and bronchiectasis displayed 
a tendency towards increased partial pressure 
of carbon dioxide, compared to COPD patients 
without bronchiectasis, however, this time the 
difference was not statistically significant (49.0 
± 11.8 vs 45.6 ± 10.6, p = 0.1). COPD patients 
with bronchiectasis and without bronchiectasis 
had similar Charlson index results (2.5 vs 2.1, p = 
0.05) (Table 2). COPD patients with bronchiectasis 
Table 1. Clinical characteristics of subjects with COPD, with and without bronchiectasis
  COPD without bronchiectasis COPD with bronchiectasis P-value
Subjects, n 259 29 —
Age (years) 70.9 ± 9.0 71.2 ± 8.6 0.88
Sex, n, M/F 160/99 17/12 0.74
GOLD combined assessment ND ND —
FEV1%pred 36.1 ± 15.5 37.6 ± 16.0 0.62
Hgb (g/dL) 14.1 ± 1.7 13.9 ± 1.8 0.26
PaO2 (mm Hg) 61.1 ± 11.5 57.6 ± 12.2 0.03
PaCO2 (mm Hg) 45.6 ± 10.6 49.0 ± 11.8 0.10
Ht (%) 43.4 ± 5.5 43.9 ± 7.1 0.60
RBC (cells/mcL) 4.5 ± 0.6 4.6 ± 0.8 0.58
6 minute walking test (m) 264 ± 133 319 ± 102 0.03
Dyspnoea before 6 mwt (Borg scale, pts) 0.5 ± 1.0 0.5 ± 0.9 0.82
Dyspnoea after 6 mwt (Borg scale, pts) 2.4 ± 2.5 2.2 ± 2.2 0.80
Hospital treatment duration (days) 16.1 ± 11.7 21.8 ± 17.9 0.02
Charlson index 2.1 ± 1.2 2.5 ± 1.0 0.05
Creatinine (mg/dL) 0.9 ± 0.3 0.8 ± 0.2 0.46
Total cholesterol (mg/dL) 187.9 ± 43.6 189.7 ± 66.1 0.88
LDL (mg/dL) 104.8 ± 25.2 86.6 ± 25.2 0.17
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required decidedly longer hospitalization during 
exacerbation, compared to patients without 
exacerbation of the disease (21.8 ± 17.9 days vs 
16.1 ± 11.7, p = 0.02). In a six-minute walking 
distance test, which was performed in the hospi-
tal ward directly after exacerbation of the disease 
during early rehabilitation, COPD patients with 
bronchiectasis covered slightly longer distance 
than patients without bronchiectasis — 319 ± 102 
vs 264 ± 133 (p = 0.03), not showing differences 
in dyspnea before or after the test. 
COPD patients with bronchiectasis signi-
ficantly more often than patients without this 
comorbidity revealed the features of colonization 
with P. aeruginosa (OR = 4.17, p = 0.02). The total 
number of potentially pathogenic microorganisms 
that were cultured in the subjects was low and 
amounted to 29%. Individuals with bronchiec-
tasis demonstrated larger quantities of positive 
results in traditional bacteriological sputum cul-
ture, i.e. 46% in the case of coexistence of COPD 
and bronchiectasis, and 27% for COPD without 
bronchiectasis (OR 2.3, p = 0.06).
Discussion
The authors of several previous studies 
concluded that the prevalence of bronchiectasis 
in patients with COPD is relatively high. In the 
study conducted by Bafadhel the prevalence of 
bronchiectasis was shown to be 27% [23]. In 
this study, all patients were actively screened 
for bronchiectasis with HRCT. Contrary to that, 
in the ECLIPSE cohort study, only 4% of patients 
with COPD had bronchiectasis [24]. Such diffe-
rence can be explained by the inclusion criteria 
of the ECLIPSE cohort, which excluded other 
pulmonary comorbidities at baseline. In our 
study we have found that 29 patients from the 
group of 288 COPD patients had been diagno-
sed with comorbid bronchiectasis. In a recent 
metaanalysis of the coexistence of COPD and 
bronchiectasis, Du [25] and Ni [26] summarized 
the data. In this metaanalysis the prevalence of 
bronchiectasis in different articles varies be-
tween 19% and 50%. According to the authors 
such a relatively high prevalence depends on 
the respective prevalence of COPD and bron-
chiectasis in the population under consideration. 
During the discussion of coexistence of COPD 
and bronchiectasis some authors concluded that 
bronchiectasis in patients with primary COPD 
can be considered a phenotype of the COPD 
spectrum. As suggested by Hurst, further work 
is needed to define pathogenesis and clinical 
consequences of this phenotype [3]. 
The discussion about the frequency of bron-
chiectasis in patients with a diagnosis of chronic 
obstructive pulmonary disease is of clinical im-
portance due to the difference in treatment mana-
gement and prognosis. Due to the methodology of 
conducted clinical trials in COPD patients, only 
some subjects who meet the criteria of COPD dia-
gnosis may be included in the randomized trials. 
The criteria that exclude from such kind of trials 
are usually comorbid pulmonary diseases such 
as bronchiectasis. Correspondingly, in the case 
of clinical trials testing drugs in patients with 
bronchiectasis, only a small part of the patient 
population may be included in the trial in which 
evaluation of therapeutic effectiveness of the me-
dication is planned. According to Chalmers et al., 
patients enrolled in randomized controlled trials 
concerning bronchiectasis are only partially repre-
sentative of patients in clinical practice, for exam-
ple only 15% of patients were eligible for trials 
with inhaled antibiotics [27]. These limitations 
of clinical trials lead to problems in choosing the 
right inhalation therapy for patients with COPD 
and bronchiectasis especially the safety of the use 
of inhaled steroids in COPD and bronchiectasis. In 
the absence of controlled clinical trials, observa-
Table 2. Microbiologic characteristics of subjects with COPD, with and without bronchiectasis
COPD without 
bronchiectasis
COPD with 
bronchiectasis
OR P-value 95% CI
Sputum culture with potentially pathogenic 
microorganism, prevalence
27.2% 46.2% 2.3 0.06 0.91–5.4
Pseudomonas aerug. prevalence 4.5% 16.7% 4.2 0.02 1.2–14.7
Klebsiella isolates,
prevalence 2.6% 0% 0.7 0.80 0.03–13
Acinetobacter isolates  prevalence 4.6% 0% 0.4 0.53 0.02–7.1
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tional studies are of great importance. In several 
large cohort studies based on administrative data 
of a big number of patients, it was found that the 
treatment with inhaled steroids in people with 
COPD may result in an increased frequency of 
pneumonia [16, 28]. Although such risk has been 
already presented in detailed analyses of rando-
mized clinical trials, the problem arose in real-life 
data analysis [28]. It is possible that the difference 
in the prevalence of pneumonia in COPD subjects 
that was observed in randomized and big cohort 
trials is caused by a considerable proportion of 
patients with bronchiectasis who were excluded 
from randomized trials and who constitute a noti-
ceable percentage of COPD patients observed in 
usual clinical practice. There also exists the pos-
sibility that as CT is not a routine examination in 
all COPD subjects, and the clinical image of both 
diseases may be similar, treatment with inhaled 
steroids is often offered to patients who, due to 
bronchial lesions such as bronchiectasis, defini-
tely should not receive such treatment. 
In the analysis present, both groups of patients 
stayed in the hospital for a relatively long time — 
16.7 days, which was partly associated with the 
protocol of the primary trial including inpatient 
respiratory rehabilitation, which was introduced 
directly after COPD exacerbation. The rehabilita-
tion lasted about a week depending on the clinical 
condition of the patient. However, patients with 
coexisting COPD and bronchiectasis stayed in 
hospital for a notably longer time. Such outcomes 
were probably affected by respiratory insufficiency 
— patients in whom bronchiectasis was diagnosed 
had the features of more severe hypoxemia. 
Another element influencing their clinical 
condition and the need for longer hospitaliza-
tion were concomitant diseases. In our study, 
the difference in the Charlson index results 
between the group of COPD with and without 
bronchiectasis did not reach statistical signifi-
cance (p = 0.05). In addition, the frequency of 
most common comorbidities was similar in both 
groups (Table 3). The frequency of observed 
concomitant diseases with COPD in our group 
generally corresponds to comorbidities observed 
in other studies [29].
In the present study, we found that the group 
of subjects with coexisting COPD and bron-
chiectasis had a slightly lower oxygen partial 
pressure, compared to COPD patients in whom 
bronchiectasis was not recognized. It may imply 
that the bronchial lesions which occur in pa-
tients with bronchiectasis are an additional 
factor influencing the severity of the disease. 
However, patients with COPD and bronchiectasis 
have shown better exercise tolerance compared 
to patients with COPD but without comorbid 
bronchiectasis. Unfortunately data collected in 
the present study does not allow to precisely 
elucidate the mechanisms of exercise tolerance 
in both studied groups.
Sputum was examined in all subjects inc-
luded in the study. The proportion of positive 
culture in the group of COPD patients amounted 
to 30%, whereas in the group of subjects with 
COPD and bronchiectasis it reached up to 46% 
but due to the limited number of patients in the 
group with bronchiectasis, this difference was not 
statistically significant. Of note is a substantial 
Table 3. Most frequent comorbidities in patients with COPD with and without bronchiectasis
Disorder, prevalence COPD without bron-
chiectasis
COPD with bron-
chiectasis
OR P-value 95% CI
Hypertension 66.0% 52.6% 0.81 0.58 0.35–1.81
Obesity 13.1% 3.6% 0.27 0.21 0.03–2.01
Thyroid diseases 15.1% 16.0% 1.04 0.92 0.31–3.22
Diabetes 20.5% 20.8% 1.01 0.97 0.31–2.88
Cancer/neoplasm 2.0 % 0% 0.78 0.87 0.06–22.62
Anaemia 34.2% 45.1% 1.57 0.24 0.72–3.43
Coronary heart disease 11.6% 11.5% 0.99 0.9 0.28–3.49
Gastric/duodenal ulcer 10.2% 3.6% 0.35 0.31 0.32–3.43
Chronic kidney disease 5.7% 0% 0.29 0.39 0.22–4.93
Home oxygen therapy 7.5% 16.3% 2.11 0.19 0.61–6.86
Chronic heart failure 8.8% 3.6% 0.40 0.38 0.12–3.14
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proportion of isolated P. aeruginosa in the case 
of patients with comorbid bronchiectasis, which 
is also similar to the values observed in other 
researches [10]. 
But looking from the actual perspective at 
the studies that we had conducted a few years 
back, we have to emphasize that the attempts to 
correlate sputum cultures with comorbidities are 
ineffective. In order to analyze the correlation 
between the bacterial loud of the bronchial tree, 
the parameters of inflammatory status and comor-
bidities, newer genetic tests, as bacterial genome 
sequencing [30] should be used.
Potentially confounding factors of the study
The original idea of the study was to estimate 
prognostic factors in acute exacerbation of COPD 
and this study design means that its results can-
not be applied to the entire population; it was not 
an epidemiological study. On the other hand, the 
present study can be valuable in identifying a real 
problem, i.e. underdiagnosis of bronchiectasis in 
the population of COPD patients. 
Conclusion
Bronchiectasis is a relatively common co-
morbidity in COPD patients. COPD patients with 
bronchiectasis are more frequently colonized 
with P. aruginosa comparing to non-bronchiecta-
sis COPD patients. We did not confirm the influ-
ence of bronchiectasis on COPD comorbidities. 
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